Founder & COOJon is a former international magazine editor with a strong background in business publications (print and digital) in the Middle East and Australia.
Actuate Therapeutics (NASDAQ:ACTU) reported successful Phase 1 results from its Actuate-1902 study on January 6, 2026.
The trial evaluated elraglusib, a first-in-class small molecule GSK-3β inhibitor, in 40 pediatric patients (ages 3–21) with relapsed or refractory solid tumors.
Atossa Therapeutics (NASDAQ:ATOS) reached a significant regulatory milestone on January 6, 2026, receiving a "Study May Proceed" letter from the U.S. FDA for its Investigational New Drug (IND) application.
Aclarion (NASDAQ:ACON) reached a significant clinical milestone on Tuesday, January 6, 2026, announcing the first patient enrollments at two prestigious new sites: Northwestern Medicine and Scripps Health.
This expansion brings the total number of active enrollment sites to four, with seven leading U.S. spine centers having completed full regulatory and operational setup.
Radware (NASDAQ:RDWR) announced Tuesday, January 6, 2026, that it has doubled its global cloud security mitigation capacity, jumping from 15 Tbps to 30 Tbps.
The massive upgrade comes in response to a "seismic shift" in the threat landscape, headlined by an 85% surge in network DDoS attacks during the first half of 2025.
Accenture (NYSE:ACN) has agreed to acquire Faculty, a prominent U.K.-based AI services and products firm, in a move that signals a major escalation in the global consulting giant's push toward "applied AI."
Natera (NASDAQ:NTRA) announced a significant clinical breakthrough today, revealing that its pivotal Phase III ALTAIR trial successfully reached statistical significance following a reclassification of patient data.
Analysts say Ethereum’s recent breakout and historical trends could set the stage for a strong first quarter rally.
Ethereum staking sentiment has strengthened as validator exits dry up and entry queues surge.
Nestle has recalled some baby formula products after identifying a potential toxin risk, urging parents not to use affected batches.
Mark Kelly has vowed to push back after the defence secretary moved to review his military rank and pension.
